Oxford Cannabinoid Techn... Share Discussion Threads

[zxie] 12/4/2023 07:31

Very good point

[zxie] 12/4/2023 07:25

We are also delighted to have received our new licence from the Home Office. The licence underpins our ability to conduct research and I'm sure the significance of this achievement will not be lost on our many stakeholders.

[zxie] 11/4/2023 16:32

Looking good today

[itscominghome] 11/4/2023 14:07

Looking to have a position long 20m eventually

[itscominghome] 11/4/2023 14:06

Bought 5m of these over the last week.

[oscar nosher] 03/4/2023 13:57

Ever wondered why the conman that hides behind the Zxie alias gets recommendations for writing shyte ?
It?s because he uses his aliases
- mr woodland
- moor sir
to recommend his posts
DIRTY FILTHY SCAMMER

[zxie] 03/4/2023 09:25

https://twitter.com/clarissamapson/status/1641771719491743747?s=46&t=D5m9d8QJFGkeuiy-jL6_TQ

[zxie] 03/4/2023 09:24

Moving 2p next

[zxie] 31/3/2023 11:35

This Phase I first-in-human clinical trial, due to commence in Q1 2023, which is being funded entirely from OCTP's existing resources, will be conducted in the UK in healthy volunteers, with a single ascending dose. The trial aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The clinical trial is anticipated to complete within Q2 2023.

[zxie] 30/3/2023 15:04

Tomorrow RNS

[sweetg] 30/3/2023 14:20

With news being so very long overdue , a day away from the end of Q1 and phase 1 not even started because no sign of approval ,. Without a press release soon with reference to why news of approval status is missing (there is a legality there as the 60 day legal limit after submission past quite a few weeks back now...) this thing risks tanking hard and fast . Just saying.

[zxie] 30/3/2023 11:06

3m buy show red

[zxie] 28/3/2023 18:00

This Phase I first-in-human clinical trial, due to commence in Q1 2023, which is being funded entirely from OCTP's existing resources, will be conducted in the UK in healthy volunteers, with a single ascending dose. The trial aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The clinical trial is anticipated to complete within Q2 2023.

[zxie] 28/3/2023 15:12

Nice volume today

[gotterdammerung] 28/3/2023 13:57

Clarissa Sowemimo-Coker
@clarissamapson
It’s a huge milestone for us and our shareholders - moving from pre-clinical to clinical is the crucial next step in our journey to put licensed medicines into the hands of patients who need them. #AskOCTP posted 24th march
All to play for now very exciting opportunities on approval.

[pillow] 28/3/2023 13:51

Yep, buyers moving in again.

[zxie] 28/3/2023 13:13

RNS any time